<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34078004</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-4527</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Immunity, inflammation and disease</Title><ISOAbbreviation>Immun Inflamm Dis</ISOAbbreviation></Journal><ArticleTitle>Long-coronavirus disease among people living with HIV in western India: An observational study.</ArticleTitle><Pagination><StartPage>1037</StartPage><EndPage>1043</EndPage><MedlinePgn>1037-1043</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/iid3.467</ELocationID><Abstract><AbstractText Label="BACKGROUND">Long-COVID is emerging as a significant problem among individuals who recovered from COVID-19. Scant information is available on the prevalence, characteristics, and risk factors for long-COVID among people living with HIV (PLHIV).</AbstractText><AbstractText Label="SETTING">A tertiary level, private, HIV clinic in western India.</AbstractText><AbstractText Label="METHODS">A prospective, observational study was conducted to assess the prevalence of long-COVID among PLHIV. Long-COVID was defined as the presence of at least one symptom after 30 days of illness onset. A questionnaire for assessing general, cardiorespiratory, neuro-psychiatric, and gastro-intestinal symptoms was used to screen individuals with history of confirmed COVID-19. Data on demographics, HIV-related variables, comorbidities, and severity of COVID-19 were abstracted from electronic medical records. Univariate and multivariate logistic regression were used to identify risk factors for long-COVID.</AbstractText><AbstractText Label="RESULTS">Ninety-four PLHIV were screened for long-COVID. Median (interquartile range [IQR]) age was 51 (47-56) years and 73.4% were males. The majority (76.6%) had a history of asymptomatic-mild COVID-19 illness. The prevalence of long-COVID was 43.6% (95% confidence interval [CI], 33.4-54.2). Moderate-severe COVID-19 illness was significantly associated with long-COVID (adjusted odds ratio, 4.7; 95% CI, 1.4-17.9; p&#x2009;=&#x2009;.016). Among individuals with long-COVID, cough (22.3%) and fatigue (19.1%) were the commonest symptoms. The median (IQR) duration for resolution of symptoms was 15 (7-30) days. Ten individuals (10.6%) had persistent symptoms at a median of 109 days since the onset of COVID-19.</AbstractText><AbstractText Label="CONCLUSION">Long-COVID is common among PLHIV with moderate-severe acute COVID-19 illness. There is a need for integration of long-COVID diagnosis and care services within antiretroviral therapy clinics for PLHIV with COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pujari</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4571-650X</Identifier><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaikwad</LastName><ForeName>Sunil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chitalikar</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabhade</LastName><ForeName>Digamber</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Kedar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bele</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Pune, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immun Inflamm Dis</MedlineTA><NlmUniqueID>101635460</NlmUniqueID><ISSNLinking>2050-4527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">India</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>20</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34078004</ArticleId><ArticleId IdType="pmc">PMC8239760</ArticleId><ArticleId IdType="doi">10.1002/iid3.467</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS&#x2010;CoV&#x2010;2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251&#x2010;2252.</Citation><ArticleIdList><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez&#x2010;Leon S, Wegman&#x2010;Ostrosky T, Perelman C, et al. More than 50 long&#x2010;term effects of COVID&#x2010;19: a systematic review and meta&#x2010;analysis. medRxiv. 2021. 10.1101/2021.01.27.21250617</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.27.21250617</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx V. Scientists set out to connect the dots on long COVID. Nat Methods. 2021;18(5):449&#x2010;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8081406</ArticleId><ArticleId IdType="pubmed">33911230</ArticleId></ArticleIdList></Reference><Reference><Citation>Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013;254(1):326&#x2010;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694608</ArticleId><ArticleId IdType="pubmed">23772629</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ministry of Health and Family Welfare, Government of India
. Clinical Management Protocol: COVID19, version 5. https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf. Accessed February 5, 2021.</Citation></Reference><Reference><Citation>
National Institute for Health and Care Excellence, Royal College of General Practitioners, Healthcare Improvement Scotland, SIGN. COVID&#x2010;19 rapid guideline: managing the long&#x2010;term effects of COVID&#x2010;19. National Institute for Health and Care Excellence, London; 2020. www.nice.org.uk/guidance/ng188. Accessed February 9, 2021.</Citation></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID&#x2010;19 in a multistate health care systems network&#x2014;United States, March&#x2013;June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993&#x2010;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID&#x2010;19 survivors in Wuhan, China: a single&#x2010;centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89&#x2010;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS&#x2010;CoV&#x2010;2 infection: the post&#x2010;COVID&#x2010;19 syndrome? ERJ Open Res. 2020;6(4):00542&#x2010;2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against COVID&#x2010;19 Post&#x2010;Acute Care Study Group . Persistent symptoms in patients after acute COVID&#x2010;19. JAMA. 2020;324(6):603&#x2010;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6&#x2010;month consequences of COVID&#x2010;19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2010;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>
Altmann D, Boyton R. Confronting the pathophysiology of long COVID. The BMJ Opinion; 2020. https://blogs.bmj.com/bmj/2020/12/09/confronting-the-pathophysiology-of-long-covid/. Accessed February 10, 2021.</Citation></Reference><Reference><Citation>Yen YF, Chuang PH, Jen IA, et al. Incidence of autoimmune diseases in a nationwide HIV/AIDS patient cohort in Taiwan, 2000&#x2010;2012. Ann Rheum Dis. 2017;76(4):661&#x2010;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">27590658</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiardini M, Muller&#x2010;Trutwin M. HIV&#x2010;associated chronic immune activation. Immunol Rev. 2013;254(1):78&#x2010;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3729961</ArticleId><ArticleId IdType="pubmed">23772616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesoriero JM, Swain CE, Pierce JL, et al. COVID&#x2010;19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021;4(2):e2037069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7859843</ArticleId><ArticleId IdType="pubmed">33533933</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MA. HIV and risk of COVID&#x2010;19 death: a population cohort study from the Western Cape Province, South Africa. medRxiv. 2020. 10.1101/2020.07.02.20145185</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.02.20145185</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbier F, Mer M, Szychowiak P, et al. Management of HIV&#x2010;infected patients in the intensive care unit. Intensive Care Med. 2020;46(2):329&#x2010;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095039</ArticleId><ArticleId IdType="pubmed">32016535</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade HB, Shinotsuka CR, da Silva IRF, et al. Highly active antiretroviral therapy for critically ill HIV patients: a systematic review and meta&#x2010;analysis. PLOS One. 2017;12(10):e0186968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655356</ArticleId><ArticleId IdType="pubmed">29065165</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiewel MA, Huson MA, van Vught LA, et al. Impact of HIV infection on the presentation, outcome and host response in patients admitted to the intensive care unit with sepsis; a case control study. Crit Care. 2016;20(1):322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056483</ArticleId><ArticleId IdType="pubmed">27719675</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association between oral corticosteroid bursts and severe adverse events: a nationwide population&#x2010;based cohort study. Ann Intern Med. 2020;173(5):325&#x2010;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">32628532</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyro&#x2010;Saint&#x2010;Paul L, Besnier P, Demessine L, et al. Cushing's syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case&#x2010;control study in the French pharmacovigilance database. J Antimicrob Chemother. 2019;74(11):3291&#x2010;3294.</Citation><ArticleIdList><ArticleId IdType="pubmed">31369085</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty&#x2010;day outcomes among patients hospitalized with COVID&#x2010;19. Ann Intern Med. 2020;174:576&#x2010;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, et al. Post&#x2010;discharge persistent symptoms and health&#x2010;related quality of life after hospitalization for COVID&#x2010;19. J Infect. 2020;81(6):e4&#x2010;e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID&#x2010;19 infection: a cross&#x2010;sectional evaluation. J Med Virol. 2021;93(2):1013&#x2010;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs. 2014;28(2):131&#x2010;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">24362768</ArticleId></ArticleIdList></Reference><Reference><Citation>Clifford DB, Ances BM. HIV&#x2010;associated neurocognitive disorder. Lancet Infect Dis. 2013;13(11):976&#x2010;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108270</ArticleId><ArticleId IdType="pubmed">24156898</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>